journal article·2026-07

Precise strategies for targeted elimination of senescent cells to combat aging and age-related diseases

Yan Chen, Danji Zhu, Wenyi Xu, Xiaoyan Miao, Zhiwei Jiang

Publisher page

Abstract

Cellular senescence is a cell fate marked by a prolonged and generally irreversible cessation of the cell cycle in reaction to stressors and certain physiological events. Senescent cells accumulate with age and contribute to the pathogenesis of various age-related diseases, such as neurodegeneration and cardiovascular disorders. In this context, eliminating senescent cells has emerged as a promising therapeutic approach, giving rise to the development of senolytic agents. Nevertheless, current senolytics lack precise selectivity and may induce off-target toxicity, highlighting the need for more precise interventions. This review summarizes recent progress in targeted elimination of senescent cells, including immunotherapy, engineered extracellular vesicles, and nano-based drug delivery systems. Additionally, we introduce their potential applications across various age-related diseases, then discuss the limitations and future development directions at length. STATEMENT OF SIGNIFICANCE: As the global population ages, age-related diseases pose a significant threat to human health and socioeconomic systems. Currently, eliminating senescent cells has become a promising therapeutic strategy. However, traditional senolytics lack precise selectivity and result in off-target toxicity and considerable side effects, highlighting the importance of targeted elimination. Building upon previous contributions, our study moves the field forward because we provide a systematic overview of recent advances in targeted strategies, including immunotherapy, engineered extracellular vesicles, and nano-based drug delivery systems. These strategies employ and process biomaterials to achieve precise clearance of senescent cells. Besides, we elucidate the molecular mechanisms of action and discuss the challenges and prospects, offering insights for improving biomaterials and therapeutic strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Telomeres, Telomerase, and Senescence · Extracellular vesicles in disease · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Senescent cells: emerging targets for human aging and age-related diseases10.1016/j.tibs.2020.03.008 ↗
2. The genetics of aging: a vertebrate perspective10.1016/j.cell.2019.02.038 ↗
3. Effects of population aging on quality of life and disease burden: a population-based study10.1186/s41256-024-00393-8 ↗
4. Hallmarks of aging: an expanding universe10.1016/j.cell.2022.11.001 ↗
5. Cellular senescence: defining a path forward10.1016/j.cell.2019.10.005 ↗
6. Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells10.1038/s41401-021-00618-3 ↗
7. Targeting cellular senescence prevents age-related bone loss in mice10.1038/nm.4385 ↗
8. Senescent cell depletion alleviates obesity-related metabolic and cardiac disorders10.1016/j.molmet.2024.102065 ↗
9. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia10.1016/j.celrep.2021.109419 ↗
10. Senolytic therapy alleviates aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model10.1038/s41593-019-0372-9 ↗
11. Senescent intimal foam cells are deleterious at all stages of atherosclerosis10.1126/science.aaf6659 ↗
12. Senescent CAFs mediate immunosuppression and drive breast cancer progression10.1158/2159-8290.CD-23-0426 ↗
13. Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy10.1016/j.semcancer.2024.05.002 ↗
14. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA10.1016/j.devcel.2014.11.012 ↗
15. The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy10.1186/s12943-025-02475-8 ↗
16. Extracellular vesicle mediated feto-maternal HMGB1 signaling induces preterm birth10.1039/D0LC01323D ↗
17. The heterogeneity of cellular senescence: insights at the single-cell level10.1016/j.tcb.2022.04.011 ↗
18. Unmasking transcriptional heterogeneity in senescent cells10.1016/j.cub.2017.07.033 ↗
19. Strategies for targeting senescent cells in human disease10.1038/s43587-021-00121-8 ↗
20. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs10.1111/acel.12344 ↗
21. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice10.1038/nm.4010 ↗
22. Cellular senescence and senolytics: the path to the clinic10.1038/s41591-022-01923-y ↗
23. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors10.1158/1078-0432.CCR-10-2616 ↗
24. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study10.1016/j.ebiom.2018.12.052 ↗
25. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence10.1111/acel.14060 ↗
26. Fisetin is a senotherapeutic that extends health and lifespan10.1016/j.ebiom.2018.09.015 ↗
27. Identification of a novel senolytic agent, navitoclax, targeting the bcl-2 family of anti-apoptotic factors10.1111/acel.12445 ↗
28. New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A115546310.18632/aging.101202 ↗
29. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results10.1038/s41591-024-02802-4 ↗
30. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging10.1016/j.cell.2017.02.031 ↗
31. Identification of HSP90 inhibitors as a novel class of senolytics10.1038/s41467-017-00314-z ↗
32. Intervention treatment reducing cellular senescence inhibits tubulointerstitial fibrosis in diabetic mice following acute kidney injury10.1042/CS20231698 ↗
33. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity10.1016/S1470-2045(10)70261-8 ↗
34. Clearance of senescent cells enhances skin wound healing in type 2 diabetic mice10.7150/thno.100991 ↗
35. Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity10.1172/jci.insight.166643 ↗
36. Cellular senescence contributes to large elastic artery stiffening and endothelial dysfunction with aging: amelioration with senolytic treatment10.1161/HYPERTENSIONAHA.123.21392 ↗
37. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation10.1038/s42003-025-07738-0 ↗
38. Senescent fibroblasts resist apoptosis by downregulating caspase-310.1016/j.mad.2004.07.007 ↗
39. Senescent cell clearance by the immune system: emerging therapeutic opportunities10.1016/j.smim.2019.04.003 ↗
40. Immunosenescence: molecular mechanisms and diseases10.1038/s41392-023-01451-2 ↗
41. Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression10.1016/j.ccell.2016.09.003 ↗
42. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L210.1038/s43018-023-00712-x ↗
43. The bystander effect contributes to the accumulation of senescent cells in vivo10.1111/acel.12848 ↗
44. A complex secretory program orchestrated by the inflammasome controls paracrine senescence10.1038/ncb2784 ↗
45. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results10.1038/s41591-025-03873-7 ↗
46. Senolytic CAR T cells reverse senescence-associated pathologies10.1038/s41586-020-2403-9 ↗
47. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates10.1126/scitranslmed.add1951 ↗
48. Targeting senescent cells with NKG2D-CAR T cells10.1038/s41420-024-01976-7 ↗
49. CAR-T cell therapy for cancer: current challenges and future directions10.1038/s41392-025-02269-w ↗
50. Role of immune cells in the removal of deleterious senescent cells10.1186/s12979-020-00187-9 ↗
51. CAR T therapy beyond cancer: the evolution of a living drug10.1038/s41586-023-06243-w ↗
52. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction10.1038/s43587-023-00560-5 ↗
53. Cytotoxic CD4(+) T cells eliminate senescent cells by targeting cytomegalovirus antigen10.1016/j.cell.2023.02.033 ↗
54. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells10.1158/2326-6066.CIR-19-0026 ↗
55. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma10.1158/2326-6066.CIR-18-0307 ↗
56. A summary of current NKG2D-based CAR clinical trials10.1093/immadv/ltab018 ↗
57. Intestinal epithelial cell endoplasmic reticulum stress promotes MULT1 up-regulation and NKG2D-mediated inflammation10.1084/jem.20162041 ↗
58. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities10.1038/nrclinonc.2017.148 ↗
59. Next-generation cell therapies: the emerging role of CAR-NK cells10.1182/bloodadvances.2020002547 ↗
60. A chimeric peptide promotes immune surveillance of senescent cells in injury, fibrosis, tumorigenesis and aging10.1038/s43587-024-00750-9 ↗
61. The biology, function, and biomedical applications of exosomes10.1126/science.aau6977 ↗
62. Extracellular vesicles as drug delivery systems: why and how?10.1016/j.addr.2020.04.004 ↗
63. Engineered extracellular vesicles modified by angiopep-2 peptide promote targeted repair of spinal cord injury and brain inflammation10.1021/acsnano.4c14675 ↗
64. Atherosclerosis: recent developments10.1016/j.cell.2022.04.004 ↗
65. Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis10.1093/eurheartj/ehz919 ↗
66. Physiological and pharmacological modulation of BAX10.1016/j.tips.2021.11.001 ↗
67. Blood exosomes endowed with magnetic and targeting properties for cancer therapy10.1021/acsnano.5b06939 ↗
68. Synchronous disintegration of ferroptosis defense axis via engineered exosome-conjugated magnetic nanoparticles for glioblastoma therapy
69. Targeted elimination of senescent cells by engineered extracellular vesicles attenuates atherosclerosis in ApoE(-/-) mice with minimal side effects10.7150/thno.87484 ↗
70. Targeted clearance of senescent cells via engineered extracellular vesicles reprograms tumor immunosuppressive microenvironment10.1002/adhm.202400945 ↗
71. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease10.1016/j.ebiom.2019.08.069 ↗
72. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice10.1038/s43587-021-00151-2 ↗
73. Nano based drug delivery systems: recent developments and future prospects10.1186/s12951-018-0392-8 ↗
74. Nanomaterials and nanomaterials-based drug delivery to promote cutaneous wound healing10.1016/j.addr.2022.114670 ↗
75. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics10.1186/s12951-023-01826-1 ↗
76. A biomarker that identifies senescent human cells in culture and in aging skin in vivo10.1073/pnas.92.20.9363 ↗
77. The senescence-associated secretory phenotype: the dark side of tumor suppression10.1146/annurev-pathol-121808-102144 ↗
78. Identification of senescent cell surface targetable protein DPP410.1101/gad.302570.117 ↗
79. Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis10.1083/jcb.202207097 ↗
80. Lipofuscin granule accumulation requires autophagy activation10.14348/molcells.2023.0019 ↗
81. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles10.1002/anie.201204663 ↗
82. Enzyme-responsive nanospheres target senescent cells for diabetic wound healing by employing chemodynamic therapy10.1016/j.actbio.2023.10.015 ↗
83. Senolytic therapy enabled by senescent cell-sensitive biomimetic melanin nano-senolytics10.1002/adhm.202401085 ↗
84. Detection and elimination of eenescent cells with a self-assembled senescence-associated beta-galactosidase-activatable nanophotosensitizer10.1021/acs.jmedchem.3c01306 ↗
85. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells10.1016/j.actbio.2024.01.002 ↗
86. Design of a magnetic nanoplatform based on CD26 targeting and HSP90 inhibition for apoptosis and ferroptosis-mediated elimination of senescent cells10.1021/acsbiomaterials.4c00771 ↗
87. Precise diabetic wound therapy: PLS nanospheres eliminate senescent cells via DPP4 targeting and PARP1 activation
88. Generation of a selective senolytic platform using a micelle-encapsulated Sudan Black B conjugated analog10.1038/s43587-024-00747-4 ↗
89. Sphingomyelin nanosystems decorated with TSP-1 derived peptide targeting senescent cells10.1016/j.ijpharm.2022.121618 ↗
90. An NIR-responsive DNA-mediated nanotetrahedron enhances the clearance of senescent cells10.1002/adma.202000184 ↗
91. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application10.1080/10717544.2021.1938756 ↗
92. Polydopamine-mesoporous silica core-shell nanoparticles for combined photothermal immunotherapy10.1021/acsami.0c10781 ↗
93. Double-network hydrogel enhanced by SS31-loaded mesoporous polydopamine nanoparticles: symphonic collaboration of near-infrared photothermal antibacterial effect and mitochondrial maintenance for full-thickness wound healing in diabetes mellitus
94. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer10.1039/C9CS00129H ↗
95. Multifunctional mesoporous silica nanoparticles for biomedical applications10.1038/s41392-023-01654-7 ↗
96. Iron-based nanomaterials for modulating tumor microenvironment10.1002/wnan.70001 ↗
97. PARP1 at the crossroad of cellular senescence and nucleolar processes10.1016/j.arr.2024.102206 ↗
98. Transcriptome signature of cellular senescence10.1093/nar/gkz555 ↗
99. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment10.1038/s41419-019-1406-7 ↗
100. Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity10.1038/s41418-024-01347-w ↗